These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39342240)

  • 1. Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B.
    Cao F; Fan T; Jiang X; Wang J; Liu Y; Zhu L; Xiong Y; Zhang S; Zhang Z; Pan Y; Li Y; Jiang C; Xia J; Yan X; Li J; Liu X; Zhu C; Huang R; Wu C
    Virol J; 2024 Sep; 21(1):234. PubMed ID: 39342240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Jeong J; Shin JW; Jung SW; Park EJ; Park NH
    Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    Suzuki K; Suda G; Yamamoto Y; Abiko S; Kinoshita K; Miyamoto S; Sugiura R; Kimura M; Maehara O; Yamada R; Kitagataya T; Shigesawa T; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    PLoS One; 2022; 17(1):e0261760. PubMed ID: 35051189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B.
    Shin H; Lim GS; Yoon JW; Ko Y; Park Y; Park J; Hur MH; Park MK; Cho Y; Lee YB; Cho EJ; Kim BH; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Med Virol; 2024 Jul; 96(7):e29760. PubMed ID: 38940453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
    Hwang EG; Jung EA; Yoo JJ; Kim SG; Kim YS
    Hepatol Int; 2023 Aug; 17(4):860-869. PubMed ID: 37099248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis.
    Tong K; Chen M; Wang D; Dai H; Peng J; Zhang J; Zhou J; Chang Y; Huang W
    Eur J Clin Pharmacol; 2024 Mar; 80(3):335-354. PubMed ID: 38197944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study.
    Zhang Q; Xu J; Liu D; Wang L; Ren S; Zheng S; Chen X; Qi L; Lu J
    Antivir Ther; 2024 Oct; 29(5):13596535241284226. PubMed ID: 39259839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
    J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
    Lim J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J
    Liver Int; 2022 Jul; 42(7):1517-1527. PubMed ID: 35343041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
    Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1673-1683. PubMed ID: 38690711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.
    Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
    Clin Mol Hepatol; 2024 Jan; 30(1):49-63. PubMed ID: 37981763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
    Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
    Liu R; Qiao J; Zhang L; Dou Z
    Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    Liu Z; Zhao Z; Ma X; Liu S; Xin Y
    BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.
    Chen JW; Cao XY; Qi X; Zhang JM
    Medicine (Baltimore); 2022 Dec; 101(50):e31980. PubMed ID: 36550809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
    Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
    Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
    Kauppinen KJ; Kivelä P; Sutinen J
    AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.